Scrip 100: What It Takes To Sell $724bn-Worth Of Drugs
This article was originally published in Scrip
The Scrip 100 is a story of fallers and risers and a changing helicopter view of the pharmaceutical industry. Data alone cannot predict individual transactions or the fates of particular pharmaceutical products. However, they do paint a clear picture of the nature of the industry and the commercial environment that companies face.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.